Harmony Biosciences Holdings, Inc.

NASDAQ:HRMY

34.05 (USD) • At close May 9, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 184.733201.267186.038172.814154.615168.412160.268134.216119.126128.308117.206107.02885.31391.21380.73273.82159.67456.28845.60938.00519.845.995000
Cost of Revenue 31.99454.40942.77838.10533.44543.15232.29625.00820.7826.88522.95918.92114.71617.81714.60412.68710.4099.9187.896.4563.4741.577000
Gross Profit 152.739146.858143.26134.709121.17125.26127.972109.20898.346101.42394.24788.10770.59773.39666.12861.13449.26546.3737.71931.54916.3664.418000
Gross Profit Ratio 0.8270.730.770.780.7840.7440.7980.8140.8260.790.8040.8230.8280.8050.8190.8280.8260.8240.8270.830.8250.737000
Reseach & Development Expenses 34.5434.66625.38763.58322.18930.30617.49914.96913.28910.09240.54812.6687.5787.45111.7396.4984.6797.6184.234.1693.4317.2764.3364.99352.99
General & Administrative Expenses 31.24328.86528.58727.22425.67627.87222.54622.80922.06222.64321.33122.16317.8818.20516.85614.30214.54713.46610.5087.6289.2913.99412.565.8923.962
Selling & Marketing Expenses 30.71127.627.57628.50727.23326.88623.41824.52822.57221.07520.46720.1617.58319.10916.4817.02215.50617.52612.60112.44313.25416.84112.9088.3786.191
SG&A 61.95456.46556.16349.7746.94854.75845.96447.33744.63443.71841.79842.32335.46337.31433.33631.32430.05330.99223.10920.07122.54430.83525.46814.2710.153
Other Expenses 0000.037-0.1410.193-0.005-0.0310.0020.0730.0560.042-0.0020.03100.004-0.020-1.525-0.400000
Operating Expenses 96.49491.13181.55113.35369.13785.06463.46362.30657.92353.8182.34654.99143.04144.76545.07537.82234.73238.6127.33924.2425.97538.11129.80419.26363.143
Operating Income 56.24555.72761.7121.35652.03340.19664.50946.90240.42347.61311.90133.11627.55628.63121.05323.31214.5337.7610.387.309-9.609-33.693-29.804-19.263-63.143
Operating Income Ratio 0.3040.2770.3320.1240.3370.2390.4030.3490.3390.3710.1020.3090.3230.3140.2610.3160.2440.1380.2280.192-0.484-5.62000
Total Other Income Expenses Net 0.9320.4280.460.338-0.248-0.507-12.677-2.807-2.643-3.51-3.934-3.885-4.171-4.156-31.575-7.223-7.147-7.966-8.471-7.336-29.011-2.747-2.095-1.3530.122
Income Before Tax 57.17756.15562.1721.69451.78539.68951.83244.09537.7844.1037.96729.23123.38524.475-10.52216.0897.386-0.2061.909-0.027-38.62-36.44-31.899-20.616-63.021
Income Before Tax Ratio 0.310.2790.3340.1260.3350.2360.3230.3290.3170.3440.0680.2730.2740.268-0.130.2180.124-0.0040.042-0.001-1.947-6.078000
Income Tax Expense -11.6176.6816.07710.10313.45113.08213.3719.7958.295-4.406-79.9765.71.91.761-0.9021.9727.127-4.3835.4216.93629.0110000
Net Income 45.5649.47546.09311.59138.33426.60738.46134.329.48548.50987.94323.53121.48522.714-9.6214.1177.386-0.2061.909-0.027-38.62-36.44-31.899-20.616-63.021
Net Income Ratio 0.2470.2460.2480.0670.2480.1580.240.2560.2480.3780.750.220.2520.249-0.1190.1910.124-0.0040.042-0.001-1.947-6.078000
EPS 0.790.870.810.20.680.460.640.570.490.821.480.40.360.39-0.170.250.13-0.004-0.14-0-0.7-0.66-0.58-0.37-1.14
EPS Diluted 0.780.850.790.20.670.450.630.560.480.791.440.390.350.38-0.170.240.13-0.004-0.14-0-0.7-0.66-0.58-0.37-1.14
EBITDA 56.24566.33272.48627.40858.15746.32170.61552.96646.48753.68117.96439.17132.75533.391-0.36128.04119.21212.14110.8229.313-7.726-31.748-28.751-19.14-63.054
EBITDA Ratio 0.3040.330.390.1590.3760.2750.4410.3950.390.4180.1530.3660.3840.366-0.0040.380.3220.2160.2370.245-0.389-5.296000